Search

Amgen Inc

Open

BrancheGesundheitswesen

442.06 -0.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

440.49

Max

446.92

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.6B

-1.8B

Verkäufe

1.4B

10B

KGV

Branchendurchschnitt

25.776

57.371

EPS

6.29

Dividendenrendite

2.36

Gewinnspanne

-18.092

Angestellte

31,500

EBITDA

-416M

3.4B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-11.06% downside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

2.36%

2.23%

Nächstes Ergebnis

3. Nov. 2026

Nächste Dividendenausschüttung

11. Sept. 2026

Nächstes Ex-Dividendendatum

20. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

22B

226B

Vorheriger Eröffnungskurs

442.46

Vorheriger Schlusskurs

442.06

Nachrichtenstimmung

By Acuity

19%

81%

40 / 340 Ranking in Healthcare

Amgen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

21. Aug. 2026, 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

20. Aug. 2026, 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

19. Aug. 2026, 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

18. Aug. 2026, 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

17. Aug. 2026, 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

14. Aug. 2026, 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

13. Aug. 2026, 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12. Aug. 2026, 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11. Aug. 2026, 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7. Aug. 2026, 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6. Aug. 2026, 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5. Aug. 2026, 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

4. Aug. 2026, 23:02 UTC

Social Media
News

Amgen reported strong Q2 results but shares are lower in after-market hours amid rising expense forecasts and the discontinuation of obesity candidate AMG 513.

3. Aug. 2026, 23:01 UTC

Amgen Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

31. Juli 2026, 20:07 UTC

News

Amgen's Board declared a quarterly dividend of $2.52 per share, while shares are trading lower amid rising Treasury yields and inflation concerns.

30. Juli 2026, 21:32 UTC

News

Amgen Inc announced a quarterly dividend of $2.52 per share, but shares are lower in after-market trading following mixed tech sector earnings.

29. Juli 2026, 23:26 UTC

Amgen Inc. shares traded roughly flat after-market, remaining above the 20-day moving average amid broader market volatility following the Federal Reserve's interest rate decision.

28. Juli 2026, 20:02 UTC

Social Media

Amgen Inc. shares are advancing, reaching an all-time high following the acquisition of Horizon, which enhances its focus on rare diseases and strategic growth areas.

27. Juli 2026, 23:22 UTC

Amgen Inc shares are higher in after-market hours, reaching a peak late in the session. Broader market sentiment remains positive amid reduced oil supply concerns.

24. Juli 2026, 23:31 UTC

Amgen Inc shares are higher in after-market trading, nearing the upper end of their one-month range. No specific news was identified to explain the movement.

23. Juli 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

22. Juli 2026, 23:11 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and positioning above its 20-day moving average.

21. Juli 2026, 23:46 UTC

Amgen Inc shares are lower in after-market hours, reflecting a modest recovery from earlier losses. No specific news was identified to explain the movement.

20. Juli 2026, 19:56 UTC

Social Media

Amgen Inc. shares are lower today, reflecting broader market trends amid geopolitical tensions and inflation concerns. The stock ranks fourth in the SCHD ETF.

17. Juli 2026, 20:02 UTC

Macro Event

Amgen Inc. shares are lower during Friday's session, despite a rise in the Michigan Consumer Sentiment Index to 54.4 in July.

16. Juli 2026, 18:02 UTC

Amgen Inc. shares are higher today, diverging from broader market declines amid rising crude oil prices and geopolitical tensions. No specific news was identified.

15. Juli 2026, 19:16 UTC

Amgen Inc shares are higher Wednesday, reflecting a positive market trend amid investor interest in biotechnology despite geopolitical tensions affecting the bond market.

14. Juli 2026, 19:16 UTC

News
Macro Event

Amgen Inc. shares are lower amid pressure from recent product recalls due to quality control issues, impacting its reputation and operational efficiency.

13. Juli 2026, 19:46 UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

Peer-Vergleich

Kursveränderung

Amgen Inc Prognose

Kursziel

By TipRanks

-11.06% Nachteil

12-Monats-Prognose

Durchschnitt 394.73 USD  -11.06%

Hoch 460 USD

Tief 230 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amgen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

23 ratings

10

Buy

11

Halten

2

Sell

Stimmung

By Acuity

40 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat